Anti-Rheumatic Rx
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Adela Castro AdelaCastro222
1 year 1 month ago
RA pearls from #ACR24 review course:
1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
2. Multimorbidity=Poor outcomes, High risk for mortality.
3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
Jiha Lee JihaRheum
1 year 1 month ago
Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person!
Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse.
@RheumNow https://t.co/NiaUXzt4nT
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.
Poster Hall